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For more than twenty years, clinical researchers have been publishing data 
regarding incidence and risk of adverse events (AEs) incurred during 
hospitalizations.   Hospitals have standard operating policies and procedures 
(SOPP) to protect patients from AE.  The AE specifics (rates, SOPP failures, 
timing and risk factors) during heart failure (HF) hospitalizations are unknown.  
There were 1,722 patients discharged with a primary diagnosis of HF 
from an academic hospital between January 2005 and December 2007.  Three 
hundred eighty-one patients experienced 566 AEs, classified into four categories: 
medication (43.9%), infection (18.9%), patient care (26.3%), or procedural 
(10.9%).  Three distinct analyses were performed: 1) patient’s perspective of 
SOPP reliability including cumulative distribution and hazard functions of time to 
AEs; 2) Cox proportional hazards model to determine independent patient-
specific risk factors for AEs; and 3) hospital administration’s perspective of SOPP 
reliability through three years of the study including cumulative distribution and 
hazard functions of time between AEs and moving range statistical process 
control (SPC) charts for days between failures of each type.  
This is the first study, to our knowledge, to consider reliability of SOPP 
from both the patient’s and hospital administration’s perspective.  AE rates in 
hospitalized patients are similar to other recently published reports and did not 
improve during the study period. Operations research methodologies will be 
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Modern health research has traditionally used the patient as the denominator for 
all quality metrics. Whether counting and recording cases of measles, broken 
bones or depression, researchers has devised both simple and complex methods 
of “counting heads” to aid in their search for understanding. Regardless of the 
specific disease studied, the disciplines of basic science, epidemiologic research 
and clinical trials all focus on the patient as the unit of measurement. While 
appropriate on a patient or personal level, this analytic framework may have 
some serious limitations when attempting to define reliability of the four major 
groupings of adverse medical events; infection, medication errors, patient care, 
and procedural. Never the less, “patient centric” traditional clinical research has 
strongly influenced the approach to the concepts of quality and safety as they 
were rapidly infused and diffused into a variety of health care settings during the 
last decade.     
The resultant cottage-industry approach to health care combined with no 
globally competitive market allowed it to ignore the basics of systems and 
industrial engineering for the preceding three or four decades.  Health care was 
sheltered from many of the pressures facing other industry sectors such as 
manufacturing that embraced these areas of expertise out of the necessity to 
survive in a new internationally competitive market.  The last  two decades in 
health care witnessed defining changes in the management of hospitals as the 
concepts of quality and patient safety, combined with technologic advancements, 
have changed the landscape of hospital operations management forever.  Now 
health care must do the same in order to improve the health of populations at an 
affordable cost without inducing more harm.   
  
xi 
My own conclusions about health care safety and systems are colored by 
not only by experiences from my profession but also from personal experience. 
Although it was enlightening and validating to see the improved clinical results of 
a clinical trial integrating hospitalist-orthopedist care on outcomes after hip 
fracture, I was surprised and perplexed when confronted with the situation of my 
Grandmother in a small critical access hospital in northern Michigan. Although 
she had a challenging hospital stay after her femur fracture,  I marveled at how 
the small town hospital “system” still managed to outperform my larger tertiary 
care organization in many ways. What concepts did my hometown hospital 
appreciate, either consciously or unconsciously, that allowed for quality care 
without the aid of electronic medical records, digital imaging or teams of 
specialists? And if these interventions could be quantified, would they be 
scalable to a larger multi-physician group, hospital, clinic, or system?  
Competitive market forces and increasing regulatory burden are forcing 
health care entities to consolidate into larger multidisciplinary clinics. These 
consolidations add new dimensions to competition as hospitals attempt to secure 
large enough patient bases to provide some financial security for the future and 
compete on perceived value of care, not just production. With these strong 
influences, health care providers and managers are actively changing their 
interpretation of the concept of reliability.  They will be shifting from a 
consideration of reliability in terms of the technology and products they use to 
deliver care (computers, laboratory machines, X-ray machines, medication 
dispensers, treatment devices such as pacemakers, etc), to thinking about the 
services they deliver from the lens of reliability.   
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Chapter 1 
INTRODUCTION 
Substantial risk is posed to hospitalized patients (Ornstein 2007, Kohn, Corrigan 
and Donaldson 2000, Leape and Berwick 2005, Landrigan et al. 2010, OIG 
2010b). This is not because of lack of national and local hospital investment in 
medical quality and patient safety initiatives.  Health care institutions have 
invested millions in improving the care of their respective patients. Public 
stakeholders have responded to this risk in hospitals with state mandates for 
public reporting of “never events” (Minnesota), payment penalties for preventable 
harm (Center of Medicaid and Medicare Services), public reporting of hospital-
level performance by the Center of Medicaid and Medicare Services, Leapfrog, 
Agency of Healthcare Research and Quality (AHRQ), etc. Another recent federal 
initiative is the Partnership for Patients, a portion of the Affordable Care Act 
legislation of 2011, which seeks to build a framework for national learning to 
increase the rate of identification and elimination of harm (McCannon and 
Berwick 2011). In spite of all of the attention given to patient safety efforts, AEs 
remain common with rates underestimated in most studies (Landrigan et al. 
2010, OIG 2010b). 
In addition to being relatively common, AEs are costly and have 
significant associated resource utilization issues.  Potentially preventable 
adverse drug events (ADEs) double the LOS and cost attributable to the ADE, 
compared to non-preventable ADEs (Bates et al. 1997). Length of stay, cost and 
mortality attributable to hospital-acquired AEs range from 0 to more than 10 
days, $50,000 and 20%, respectively (Zhan 2003). In another study, AEs 
  2 
occurring in the ICU added an average of 31 days in the hospital (Forster et al. 
2008).  
We will focus our research on patients hospitalized with a primary 
diagnosis of heart failure (HF), the most common inpatient diagnosis in the 
U.S.A. (Kozak, DeFrances and Hall 2006). Limiting patient selection to a single 
primary inpatient diagnosis will address some issues of patient heterogeneity and 
resultant unknown collinearity found in current patient safety literature. HF is also 
a prime target for investigation as one of the largest public health concerns in the 
U.S.A. (Kozak, DeFrances and Hall 2006, Lloyd-Jones et al. 2010). HF was the 
most common cause of hospitalization for patients over 65 years of age in 2009, 
accounting for more than 762,000 hospitalizations and $10.7 billion where HF 
was the principal Medicare diagnosis (Wier et al. 2011).  The sheer volume of HF 
patients implies that they are exposed to the workings of the systems and 
processes of inpatient healthcare delivery on a scale larger than any other 
patient diagnostic group.  Through the 1980’s and 1990’s there was an increase 
in the severity of heart failure with increase in number of invasive procedures and 
a decrease in hospital mortality (Polanczyk et al. 2000).  As the American 
population ages, we can only expect this group to become an even larger 
proportion of our inpatients as patients survive to later ages with larger burdens 
of comorbidity.  
With HF and AE being two of the largest public health concerns and the 
topics of many academic and lay publication, it is surprising that there is a void of 
literature at the interface.  This research builds upon traditional epidemiologic 
clinical research and adds three new pieces of analysis to the existing body of 
patient safety research 1) epidemiology of AEs in HF patients with patient-
  3 
specific risk factors; 2) hazard of experiencing an AE from the patient’s 
perspective; and 3) reliability of this institution’s standard operating procedures 
and policies that serve as AE prevention measures. 
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Chapter 2 
LITERATURE SURVEY 
To Err is Human: In the years that have passed since the publication of the 
Institute of Medicine’s To Err is Human report (Kohn, Corrigan and Donaldson 
2000), health care organizations across the country have expended enormous 
energy and resources to improve the safety of health care delivery. However, 
there remains an ever-growing national concern regarding perceived less than 
ideal improvements in safety and quality of health care delivery since the release 
of this report (Longo et al. 2005, Wachter 2004, Berwick, Nolan and Whittington 
2008). This report was based on data that already existed in the medical 
literature but had received little attention.  For example, the Harvard Medical 
Practice Study reported an incidence of adverse events to be 3.7% of New York 
hospitalizations in 1984 (Brennan et al. 1991). The Colorado and Utah, 
Canadian, Greater London, and the Australian studies reported rates between 
2.9 – 16.6% (Thomas et al. 2000, Wilson, Harrison and Gibberd 1999, Gawande, 
Thomas and Zinner 1999, Neale, Graham and Woloshynowych 2001, Baker et 
al. 2004). More recently, studies have reported AE rates as high as 27.7% (OIG 
2010b, Landrigan et al. 2010). These studies were most often descriptive and 
reported basic frequencies of events, with only a few designed to determine risk 
factors of AEs.  None of these studies evaluated the interactions of patient and 
health care delivery system factors as they contributed to not only the occurrence 
of the AEs, but also to the severity of iatrogenic illness that results.  
Adverse event definition: The range of AEs occurring during hospitalizations 
varies widely as reported above. Explanations for the variable estimates include 
differences in methodology of AE detection and lack of consensus on definitions 
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and taxonomy.  Yu and Nation (2005) found eight different definitions of AEs with 
three different functional meanings.  From here forward, an AE is defined as an 
unanticipated illness or injury caused by medical evaluation and/or management 
rather than by the underlying disease or condition of the patient (Kohn, Corrigan 
and Donaldson 2000). Presence, or absence, of an error or distinction of 
preventability was not considered in this study. 
Risk factors for adverse events: Both the patient and the health care delivery 
system can manifest risk for the occurrence of AEs.  The elucidation of patient- 
and/or system-specific risk factors for an AE was the focus of several clinical 
studies.  Some of these independently predictive risk factors (identified with 
regression or Cox proportional hazards analyses) for the occurrence of an AE 
during a hospitalization are listed in Table 1. 
The majority of risk factors for AEs appear to be based on the patient’s 
health or personal characteristics such as age. System-specific factors are 
infrequently studied. An example of the importance of understanding both 
aspects of this risk relates to unplanned hospital readmission for HF patients.  
Unplanned readmission to the hospital is considered a marker of diminished 
quality of care. If the readmission is a consequence of care delivered by the 
hospital, then it is also considered an AE.   For HF patients, there are many 
patient-specific risks or causes of readmission.  Some include compliance with 
medication and diet or multiple other comorbidities and lack of social support at 
home.   However, from a system of care delivery perspective, failure of providers 
to document the delivery of the discharge education mandated by the Joint 
Commission on Accreditation and Healthcare Organizations is, in-and-of itself, 
associated with unplanned hospital readmission [68% of the patients studied 
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received all of the discharge instructions and had a significant decrease in 
number of hospital readmissions (p=0.003)] (VanSuch et al. 2006). 
Heart failure and adverse events: The vast majority of inpatient AE research 
focuses on medication-related events and is performed in general medical and 
surgical populations.  The wide range of disease, in these primarily tertiary care 
referral centers, makes it difficult, if not impossible, to account statistically for all 
of the possible confounding factors that may influence measurement and 
analysis of rates and outcomes of adverse events.  There is a paucity of data in 
the literature regarding adverse events and their outcomes in more 
homogeneous populations, such as those admitted with the same diagnosis, 
which would eliminate a few of the concerns regarding confounding in the 
analysis.   
Heart failure, accounting for the largest number of hospitalizations in a 
year for any single diagnosis (Kozak, DeFrances and Hall 2006), combined with 
its ranking as one of the most significant public health concerns, makes an 
excellent inpatient model on which to study AEs and their untoward effects with 
iatrogenic illness. In an Olmsted County epidemiology study 83.1% of patients 
were hospitalized during a mean (SD) period of 4.7 (3.9) years following their 
initial HF diagnosis (Dunlay et al. 2009). Medicare HF patients have a forty 
percent 90-day readmission rate following a discharge of a HF hospitalization 
(Krumholz et al. 1997). The incidence of HF is rising and these patients are 
surviving longer (Lloyd-Jones et al. 2010). The chronicity of this disease with 
need for recurrent hospitalizations exposes this aging and growing population to 
the problems of inpatient health care delivery at a larger scale than any other 
clinical subgroup of patients.  
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There is abundant HF clinical outcomes research; yet curiously, there is a 
marked paucity of information regarding AEs and iatrogenic illness during a 
hospitalization for HF.  There were only three studies that specifically discussed 
AEs in this population.(Fanikos et al. 2007, VanSuch et al. 2006, Sztramko, Chau 
and Wong 2011).   
Adverse event detection: In order to for a health care organization to learn about 
hazards in care delivery unintentionally endangering patients and employees, it is 
essential to identify health care delivery failures, or AEs.  It is necessary to 
investigate inciting causes in order to mitigate future harm.  However, identifying 
failures in SOPP in the care system that lead to adverse events is challenging 
and often not obvious.  Very rarely is a SOPP failure a hard failure, e.g. resulting 
in a patient death, which would be easier to detect. As a result, there is a fair 
amount of research investigating and comparing methodologies for AE 
identification and classification (Murff et al. 2003, Yu and Nation 2005, Melton 
2005).  
All Joint Commission certified hospitals have AE or safety, reporting 
policies and processes for health care providers.  The most common method 
utilized by hospitals is a voluntary reporting process (incident and prompted).  
Others utilize an involuntary (chart review, observers, patient interviews) or 
electronic data sources (single, multiple, rule-based alert logic, some using 
natural language processing); often in combination with the voluntary reporting 
systems.   
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Naessens et al. (2009) reported a comparison of three widely used 
detection methods (GTT, AHRQ’s patient safety indicators (PSI), and voluntary 
reporting).  The AHRQ’s PSI are a set of adverse events defined by a computer 
algorithm run on administrative data sources using secondary diagnosis codes.  
They found that each of the different methods identified different types of events.  
The investigators determined that less than 10.5% of events identified through 
one method were detected with other methods (Naessens et al. 2009). So while 
chart review is considered the gold standard; it is labor intensive, introduces bias 
issues inherent in all retrospective studies, and potentially misses a significant 
amount of harm occurring during hospitalizations.  Combination methods are 
likely to yield increased opportunities for organizational learning by increasing the 
yield of detection.   
Active surveillance (concurrent to patients hospitalizations) using 
electronic triggers (laboratory findings or detection of use of certain predefined 
medications often associated with an adverse event) are increasing in use as 
technology and increased use of electronic medical records have advanced. 
Electronic surveillance for triggers without incorporation of logic-based rules 
limits the personnel needed for screening, but still requires clinical interpretation 
to determine if an adverse event occurred or if the clinical condition was an 
expected progression or course of illness (Szekendi, Sullivan and Bobb 2006). 
The addition of natural language processing to allow for incorporation of cues 
from clinical documentation increase the positive predictive value of the triggers 
reported (Melton 2005).  
To be consistent with recently published research (OIG 2010a, OIG 
2010b, Landrigan et al. 2010), the GTT was used to identify AE. This involved a 
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two-phased approach to chart review as previously used for the majority of the 
major AE studies (Leape et al. 1991, Thomas et al. 2000, Wilson, Harrison and 
Gibberd 1999, OIG 2010a, Landrigan et al. 2010, Naessens et al. 2010, Baker et 
al. 2004).  One of the problems with relying on chart review for identification of 
the primary outcome is the variable clinical documentation in the record and 
varying rates of physician agreement regarding assessment of AE presence.  
The agreement reported in the literature has kappa statistics varying between 
0.40 to 0.61 (Localio 1996, Thomas Lipsitz and Studdert 2002, Sharek et al. 
2011).  The GTT uses a two-phase approach, but since it requires two nurses for 
identification of triggers and does not require MD agreement, the inter-rater 
(nurses) reliability is higher (Naessens et al. 2010). 
Reliability in Health Care Delivery:  The discipline of reliability is not well defined 
in the process or service aspects of health care delivery, as compared to medical 
diagnostic equipment and durable goods.  As an example, if dismissing a HF 
patient from the hospital were considered a process that should be reliably 
executed, than a 40% readmission rate for Medicare HF patients (Fonarow et 
al.1997) would be considered a highly unreliable process. Furthermore, if the 
goal is to improve the reliability of this process for HF patients, then 
documentation of an 80% improvement in this process by one hospital (Fonarow 
et al.1997) more than a decade ago, should have been adopted readily by all 
hospitals by now.   
One key indicator of the lack of reliability of health care delivery is 
manifested in the tremendous variability in expenditures and outcomes for 
common diseases across the United States and world.  The Commonwealth 
Fund Commission on the High Performance Health System and the Dartmouth 
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Atlas both published evidence painting U.S. health care delivery in less than a 
favorable light.  The U.S. received a score of 64 out of 100 overall score from the 
Commonwealth Fund Commission in comparison to the best performing 
industrialized nations (McCarthy et al. 2011)  In fact, the U.S. ranked last 
compared to the 16 other countries in regards to possibly preventable death.  
This is defined as mortality that could be avoided if chronic medical conditions 
(e.g. diabetes mellitus) were treated most effectively to yield outcomes similar to 
the best performing countries.  This 2011 report estimates that up to 91,000 
American lives could be saved if the American health system performed at the 
level of the leading country (McCarthy et al. 2011). In addition to international 
variation, the Dartmouth Atlas of Health Care reported that the hospitalization 
rate for HF varied significantly by state from 8.7 to 29.3 per 1,000 Medicare 
enrollees in 2007 (Dartmouth Atlas of Health Care 2012). 
 One interpretation for this wide variability in health care performance is a 
lack of reliability in the delivery of health care. In 2004, the Institute of Healthcare 
Improvement (IHI) released a whitepaper entitled “Improving the Reliability of 
Healthcare”.  This report defined reliability principles in health care as the 
“methods of evaluating, calculating, and improving the overall reliability of a 
complex system” that will be required “to improve both safety and the rate at 
which a system consistently produces appropriate outcomes” (Nolan, Haraden 
and Griffin 2004). Their report was technically superficial and did not include the 
detailed quantitative and scientific aspects required for appropriate engineering 
study of the reliability of a product or service.  
There is a paucity of information in the published literature regarding the 
translation of scientific reliability principles into health care environments.  Yet, 
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there is some evidence of its application.  Many health care systems view 
concepts of reliability through the lens of compliance with external rules and 
regulations.  Although not defined by most health care systems as reliability of 
their processes, participants of IHI’s 5 Million Lives Campaign were encouraged 
to adopt the concept of bundles for some higher risk areas of care provision (IHI 
2012b). A bundle is a group of three to five evidence-based interventions or 
processes of care that are derived from the literature and all necessary to ensure 
the best possible outcomes for patients (IHI 2012a, Levy et al. 2004). These 
bundles, when implemented according to IHI’s definitions, are considered to be in 
a binary state (success or failure) with a hard failure measurement – the bundle 
ceases to function as a synergistic set of interventions when even one aspect is 
not carried out.  As a portion of this work, compliance measurements with the 
bundle implementation report time [days] between episodes of central line-
associated blood stream infection or events per 1000 ventilator days – thus 
moving away from the patient as the unit of analysis and promoting a reliability 
metric of performance through time.   
Pogorzelska et al. (2011) reported a key research finding regarding use of 
a ventilator bundle on rates of the hospital-acquired infection, ventilator 
associated pneumonia (VAP).  Of 415 intensive care units in 250 hospitals, two-
thirds reported adoption of a VAP-prevention bundle.  Sixty-six percent of the 
ICU’s had monitored the implementation of the bundle and only 39% reported 
high compliance. The primary outcome of this study (VAP) was reported in 
events per 1000 ventilator days and not by patient, which is the unit of analysis in 
most clinical research studies.  They found that compliance with the bundle 
process was associated with a significant reduction in VAP (β = -1.81, P< 0.01). 
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While IHI defines evidence-based bundles as having a binary state 
function for the purposes of compliance measurement, the groups of standard 
operating policies and procedures have a more multi-state function in bedside 
application.  For example, providers can be completely, partially compliant with 
infection control policies and procedures.  The outcome of the policy then can be 
a soft failure – a partial loss of function.  In this case, a patient may not become 
victim to the colitis that is spreading on the floor, but may obtain a urinary tract 
infection from an indwelling catheter that remained in too long. 
Adverse events and reliability: Like the bundles promoted by IHI to improve 
outcomes, there are a number of standard operating policies and procedures 
(SOPP) that are ubiquitous across hospitals accredited by the Joint Commission. 
These SOPP standards are required to maintain hospital accreditation.  The Joint 
Commission also has a set of published National Patient Safety Goals, which are 
measured, monitored and reported publically.  The SOPPs set forth by the Joint 
Commission standards and goals include infection prevention, safe medication 
delivery, universal precautions for safe peri-procedural care, and injury and 
illness prevention (e.g. falls, skin tears, readmissions).  Standard of care also 
dictates the following of safe medication indication and dosing guidelines 
published by the Food and Drug Administration.  These SOPP are necessary to 
prevent injury to patients during their hospitalizations.  The reliability of these 
SOPP for the prevention of AE during HF hospitalizations, or through time, is 
unknown.   
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Chapter 3 
METHODOLOGY 
Study design and setting:  A retrospective cohort evaluation based on review of 
the clinical record and institutional administrative data sources was conducted at 
an academic, tertiary care medical center with two hospitals and 1,500 beds in 
Rochester, Minnesota.  Prior to proceeding with any patient cohort identification 
or data collection, a study protocol was reviewed by the Mayo Clinic Institutional 
Review Board.  This study was considered to be of minimal risk to participants 
and granted approval to proceed without direct patient contact.  Only those 
patients who authorized the use of their medical records for research were 
considered eligible (Melton 1997). 
Study participants:  Patients discharged from the hospital with a primary 
diagnosis of HF from January 1, 2005 through December 31, 2007 were eligible 
for the study.  Study participants were identified by searching the administrative 
data for the following Medicare diagnosis-related group (DRG) 127 (ICD-9) 
codes:  acute HF (428.9); combined systolic and diastolic failure (428.40-428.43); 
non-specified heart failure (428.0); hypertensive heart disease with HF (402.91); 
systolic HF (428.20-428.23); diastolic HF (428.30-428.33); and rheumatic heart 
failure (396.30).  Only those who met the Framingham Criteria for HF (McKee 
1971) were included in the final patient cohort.  When multiple hospitalizations 
occurred within the study period, only the first hospitalization was included in 
order to maintain statistical assumptions of independent observations in the 
analysis.  Potential subjects were excluded from the study cohort if they had any 
one of the following:  congenital heart disease, severe leukopenia (absolute 
neutrophil count less than 500 WBC/mm3), active chemotherapy or radiation 
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therapy, an admission for palliative care, or a hospitalization less than 24 hours.  
In an effort to maintain, as much as possible, a homogeneous study population, 
we limited the study to medical portions of HF admissions.  Those who later 
required major surgery as a portion of their hospitalization were censored on the 
day of surgery. 
Study adverse event definitions:  This study focused on AEs as opposed to 
errors.  The Institute of Medicine (IOM) defines a medical error as “the failure to 
complete a planned action as intended or the use of a wrong plan to achieve an 
aim,” whereas an AE is defined as “an injury caused by medical management 
rather than by the underlying disease or condition of the patient” (Kohn, Corrigan 
and Donaldson 2000).  Adverse outcomes caused solely by the underlying 
disease or intended consequences of treatment were not considered AEs.  AEs 
were categorized into one of 4 areas: infection, medication, patient care, or 
procedural.  Medication events were screened using the Naranjo algorithm 
detailed in Appendix B (Naranjo, Busto and Sellers 1981). Severity of the events 
ranges from those with transient harm requiring incremental testing or treatment, 
to significant permanent harm, or death. Definitions and examples of these 
adverse event categories are detailed in Table 2. 
Detection of Adverse Events: AEs were identified using a two-stage review, as 
reported in our prior work (Naessens et al. 2006). The Global Trigger Tool (GTT) 
(Resar et al. 2003; Rozich et al. 2003) was used to detect potential AEs during 
each patient’s indexed HF hospitalization.  The triggers are patient symptoms, 
laboratory findings, medications, or infections often associated with AEs.    This 
trigger approach allowed the reviewer to focus only on those portions of the 
medical record where these data are found, thus decreasing the amount of time 
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reviewers spend evaluating a particular record.  All nurse and physician GTT 
reviewers underwent formal training, and each reviewed medical records in a 
random order.  A specifically designed, web-based, data-capture tool was used 
to facilitate uniform data collection and to streamline the independent reviewers’ 
workflow, reconciliation process, and capture of all evaluations into a single 
source (Naessens et al. 2010).  Two nurses, blinded to other reviews, 
independently reviewed each hospital record to identify triggers and record 
details of clinical care occurring near the time of the trigger.   
The physician reviewers carefully reconciled nurses’ findings with the medical 
record and made the final determinations regarding the presence and severity of 
an AE versus an expected course of care.  The inter-rater reliability for nurses 
and between physician and nurse reviewers was previously reported as 
adequate within our institution (Naessens et al. 2009), and recently recounted by 
Landrigan et al. (2010) and Sharek et al. (2011). The process for determining 
presence or absence of an AE from the GTT is delineated in Figure 1. 
The severity of AEs was classified according to the National Coordinating 
Council for Medication Error Reporting and Prevention (2001, NCC MERP) as 
outlined in Table 3.  Events were included if they were classified as NCC MERP 
level E (temporary harm with documented patient symptoms or intervention) or 
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Table 2: Definitions and examples of adverse event categories 
Adverse Event Definition 
Infection Presence of one or more positive cultures obtained at least 48 hours 
following admission in a clinically ill patient.  If there is a possibility 
that the culture result is a contaminant, then the following criteria 
must be met in order for a nosocomial infection to be diagnosed:    
1) presence of an intravascular catheter (for blood stream 
infections) or endotrachial tube (ventilator associated pneumonia) or 
presence of a urinary catheter (for urinary tract infections) or 
characteristic infiltrate on chest xray (for pneumonia); 2) initiation of 
antibiotics; and 3) any one or more of the following: chills, fever > 
38.0 or < 36.0, or systolic BP < 90 mmHg.   
Example: Catheter associated urinary tract infection 
 
Medication Illness as an unintended consequence of medication prescription 
and/or administration of a medication. Causation will be assessed 
with the Naranjo algorithm (Appendix B) 
Example: Narcotic-induced respiratory failure 
Patient care Illness as a consequence of evaluation or treatment, including 
failure to recognize a serious illness that leads to temporary or 
permanent harm. 
Example: Fall 
Procedural Injury as an unintended consequence of a diagnostic or therapeutic 
procedure 
Example:  Hematoma at intravenous catheter site 
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For instance, documentation of a fall with “no injury” recorded in the 
record did not meet the NCC MERP criteria for an E level harm and therefore 
was not included as an AE.  Possible AEs with symptoms present at the time of 
admission were not included in this study.  Detailed descriptions for each AE 
were collected and managed using REDCap electronic data capture tools hosted 
at Mayo Clinic (Harris et al. 2009).  
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Table 3: NCC MERP severity of adverse event definitions and examples 




Event/error occurred that reached 
the patient and required monitoring 
to confirm that it resulted in no harm 
to the patient and/or required 
intervention to preclude harm 
 
 
Fall with no documented injury 
 
E Event/error occurred that may have 
contributed to or resulted in 
temporary harm to the patient an 
required intervention 
Catheter associated urinary tract 
infection 
 
F Event/error occurred that may have 
contributed to or resulted in 
temporary harm to the patient and 
required initial or prolonged 
hospitalization 
Retroperitoneal hematoma in a 
patient with supratherapeutic anti-
coagulation treatment 
G Event/error occurred that may have 
contributed to or resulted in 
permanent patient harm 
Renal toxicity requiring ongoing 
hemodialysis 
H Event/error occurred that required 
intervention necessary to sustain life 
Narcotic-induced respiratory failure 
requiring transfer to ICU 
I Event/error occurred that may have 
contributed to or resulted in the 
patient’s death 
Fatal pulmonary embolus in patient 
not receiving DVT prophylaxis  
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Reliability:  Reliability is technically defined as “the probability that a product [or 
service] performs its intended function without failure under specific conditions for 
a specified period of time” (Yang 2007).  There are several operational 
components to this definition that warrant clarification for this study: product or 
service, intended function, specific conditions, and specified period of time.  The 
service and intended function in this study is the group of standard operating 
policies and procedures (SOPP) designed for the prevention of patient harm 
occurring as an unintended consequence of evaluation and treatment.  The 
specific condition is a hospitalization for an episode of HF.  The specified period 
of time is segmented by two differing perspectives: Model A) from the patient’s 
perspective, the duration of a hospitalization for HF; Model B) from the hospital 
administration’s perspective, all HF hospitalizations during the calendar years 
2005 - 2007.  Reliability will be assessed and analyzed from each of these 
perspectives.  Figure 2 depicts the 4 major categories of SOPP in hospitals.  
Each of the SOPP is considered independent shaped by relative evidence-based 
guidelines published by national trade organizations and governmental agencies.  
The AE resulting from failures of the individual SOPP are therefore independent 
as well.  However, failure of a SOPP more than once during a single 
hospitalization for a single patient may not be an independent occurrence.  
Therefore, only the first failure of each individual SOPP is considered in the 
analyses where the patient is the unit of analysis. 
 For the purposes of this study, reliability will be considered to be a multi-
state function.  Complete or partial success of SOPP are both measurable 
outcomes. It is possible for some portions of a SOPP to fail while others continue 
functioning through time.  For example, the standard of care for medication 
  21 
selection may be met, but the initial dose selected may be too high for a patient’s 
clinical condition and they suffer an adverse drug event.  The reliability of each of 
the four main SOPP represented in this study (infection control, safe medication 
delivery, injury and illness prevention and universal precautions and safe 
practices for procedures) will be assessed as both mean time to failure as well as 
mean time between failures.  The cumulative density function (cdf), F(t), and the 
hazard function, denoted h(t), will both be determined.  The cumulative density 
function is defined as the probability that a component of the SOPP will fail, 
resulting in an AE, by time t.  In the case of this study, time t has been selected 
to be both end of day one of hospitalization and day 4 (median duration of 
hospitalization for HF).  The hazard function delineates the instantaneous failure 
rate for HF patients who have survived to a point in the hospital without already 
having an AE.   
Definition of outcome (dependent) variables:  The primary outcome variable for 
all of the analyses is time to failure.  In this study, an AE is considered a failure of 
the SOPP to prevent harm during the HF hospitalization. Time to AE is evaluated 
from the two distinct perspectives illustrated in Figure 3.  The first (Model A: 
patient perspective) uses the individual patient as the primary unit of analysis.  
Within Model A, there are two different types of analyses performed.  The first 
evaluates possible patient-specific characteristics as risk factors for developing 
an AE during their HF hospitalization.  The second group of analyses in Model A 
(patient perspective) evaluates to first AE, regardless of cause, and time to the 
first AE of each of the four types.   
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Figure 2: Standard operating policies and procedures utilized in hospital 
health care delivery to prevent risk of adverse events secondary to failures 
of any of these processes 
 
These patient-level analyses view the risk of experiencing an AE from a patient’s 
perspective as mean time to failure.  Types of questions that could be answered 
from the patient-level analyses include the following: 1) Do I have any personal 
characteristics or comorbidities that increase my risk of having an AE? 2) What is 
the chance that I will have an AE given that I have been in the hospital for 4 
days?  3) What is the cause of that AE likely to be?  Knowing when the failure 
rate is highest for patients and what they are most likely to experience may help 
mitigate harm at the bedside for a particular patient by educating both care 
providers and the patients themselves of these vulnerabilities. 
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 In the second approach (Model B: administration perspective) the 
reliability of each SOPP through time is the primary consideration.  In this case, 
the time between failures of SOPP is investigated.  The time between these 
failures is important for hospitals’ administrations to understand if the work they 
are doing to improve safety is yielding expected results; thereby, increasing the  
failures.  Examples of questions that could be answered from this system-level 
perspective include the following: 1) What is the hazard of failure of any, or all, of 
the SOPPs through time (2005-2007) for hospitalized population of HF patients?  
2) What type of hazard were the hospitalized population of HF patients exposed 
to between 2005 and 2007? 3) What is the mean time between failures? Is the 
hospital performance improving or degrading through time? 
 
Definition of patient-specific variables (independent covariates):  Baseline 
characteristics were abstracted from the medical record and administrative data 
sources.  Age, gender, social habits (tobacco or alcohol use), number of 
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admission medications, and documentation of comorbid medical conditions were 
taken from physician documentation in the clinical medical record.  A patient’s 
baseline status, or pre-hospitalization health is an important aspect of their 
inpatient health care experience.  The severity of their illness, complexity of 
multiple chronic illnesses and abilities to independently care for themselves or 
move around in their room, dictates the intensity of treatments and hands-on 
care provided by hospital staff.  Several categories of patient-specific variables 
(covariates) were included in the analysis.  Table 4 provides study definitions for 
each of the demographic and social covariates used in the statistical analyses.  
Functional status, a person’s ability to independently perform their activities of 
daily living and ambulatory status are key components of overall health.  Those 
who are dependent upon others for completion of their activities of daily living 
(bathing, dressing, eating, toileting or housekeeping) have a different hospital 
experience than those who are completely independent for their own cares. The 
covariates used to measure functional and ambulatory status are defined in 
Table 5.   Another important measure of health is burden of chronic disease.  The 
patient-specific chronic medical conditions utilized as covariates are listed in 
Table 6 and defined in detail in the glossary.  Medical treatments for these 
chronic conditions contain their own risks of side effects or AEs.  The classes of 
medications patients were taking at the time of admission are listed in Table 7 
and were included as covariates in the model.   Finally, some covariates required 
calculations to be performed from clinical data abstracted from the medical 
record.  The definitions of these calculated covariates are detailed in Table 8.  All 
of the covariates listed are time independent; therefore, are time-fixed and do not 
change through the hospitalization. 
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Table 4: Definitions of patient demographic and social covariates 
 
Covariate Definition 
Age Continuous variable of length of time in years from date of patient’s 
  birth to the date of admission to the hospital 
Gender Categorical variable of gender (male or female) 
Residence Categorical variable referring to the geographical location of  
  patient’s primary residence.  Patients were considered local if they 
  resided within 120-mile radius of Rochester, MN.  Patients who  
  lived beyond this distance were categorized as ‘national’. 
Marital status Categorical variable indicating patient’s marital status (married or  
  not married) 
Type of home Categorical variable for type of living situation (home, assisted living  
  or skilled nursing facility)  
Tobacco use Categorical variable of current tobacco use in any form: current,  
  former or never 
Alcohol use Categorical variable of any amount of alcohol use 
Transfer from      
  another hospital 
Categorical variable indicating if patient was hospitalized in a  













  status 
Five categorical variables indicating independence or dependence 
  with each of the following activities of daily living: eating, bathing, 
  dressing, toileting and housekeeping. 
Ambulatory 
  status 
Five categorical variables indicating the degree of assistance required 
  for basic movement or ambulation: walk completely independently, 
  walk with assistance of a device (cane or walker), use of a 
  wheelchair or motorized vehicle required in the home, assistance 
  needed for any changes in position (standing to sitting, bed to chair, 
  etc.), or completely bedridden. 
Table 6: List of chronic diseases included as covariates 
 
Asthma/COPD Diabetes mellitus Osteoporosis trial arrhythmia Heart failur /Cardiomyopathy Pac maker/defibrillator 
Autoimmune disease Home CPAP PUD/GI bleed 
Cancer Home oxygen PVD 
Cerebrovascular disease Hyperlipidemia Pulmonary embolus 
Chronic kidney disease Hypertension Renal transplant 
Coronary artery disease Myocardial infarction Severe aortic stenosis 




COPD: chronic obstructive pulmonary disease; CPAP: continuous positive airway 
pressure; PUD: peptic ulcer disease; GI: gastrointestinal; PVD: peripheral vascular 
disease. Comorbidity definitions are found in the glossary. 
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Table 7: List of medication classes Patients were taking at the time of 
admission 
 
Asthma/COPD Diabetes mellitus Osteoporosis llopurinol Coumadin In ulin 
Amiodarone Digoxin Nitrates 
ACE-I or ARB Diuretic NSAID 
Aspirin GI protection Oral diabetes medication 
Other antiplatelet HMG-CoA reductase inhibitor Potassium supplementation 
Beta blocker Hydralazine Prednisone 
Calcium channel blocker   
ACE-I: Angiotensin converting enzyme inhibitor; ARB: Angiotensin II receptor blocker; 
NSAID: Nonsteroidal anti-inflammatory drug; Other antiplatelet: ticlopidine, clopidigrel, 
prasugrel, dipyridamole; Oral diabetes medications: sulfonylureas, biguanides, 
thiazolidinediones, alpha-glucosidase inhibitors, meglitinides, dipeptidyl peptidase IV 
inhibitors; GI protection: Histamine 2 receptor blocker or proton pump inhibitor. 
Definitions are found in the glossary. 
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Table 8: Definitions of patient-specific calculated covariates 
 
Covariate Definition and/or calculation 
BMI Body mass index = mass (kg) / (height(m))2 
Charlson (1987) 
Index 
Weighted index of comorbidity.  The score reflects the additive burden 
of chronic diseases and has been used in longitudinal and in-patient 
mortality prediction studies.  (Binary data points summed to yield the 
score include history of the following: myocardial infarction, congestive 
heart failure, peripheral vascular disease, cerebrovascular disease, 
dementia, chronic pulmonary disease, connective tissue disease, ulcer 
disease, liver disease mild, diabetes, hemiplegia, renal disease 
moderate to severe, diabetes with end organ damage, any 







Weighted index of acute illness derived and validated as a mortality 
prediction tool in elderly medical patients, including patients with HF.  
Each of the 12 physiological measurements included were given a 
point value of 6, 4, 3, or 2 based upon the adjusted odds ratio of the 
variable’s association with inpatient mortality.  All measurements are 
taken within the first 48 hours of admission. These variables (point 
values assigned for abnormal results) include: level of consciousness* 
(6), highest bilirubin (4), O2 saturation* (4), highest blood urea 
nitrogen (4), lowest glucose (3), lowest albumin (3), lowest sodium (3), 
diastolic blood pressure* (3), highest white blood cell count (3), highest 
glucose (2), systolic blood pressure* (2), highest creatinine (2).  
Maximum raw score is 39 points. Higher values indicate elevated 
severity of acute illness at time of presentation to the hospital. [* only 
the first value recorded within 48 hours of admission]   
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Chapter 4 
DATA ANALYSIS AND RESULTS 
All data analyses were performed using JMP version 9.0.3 (SAS Institute Inc., 
Cary, North Carolina). 
Adverse event descriptive analyses: Two different ratios were utilized to estimate 
rates of overall AEs: number of events per 100 patient discharges and number of 
events per 1000 patient days.  AEs were categorized and reported in two ways: 
1) by severity according to the NCC MERP; and 2) by type of AE (infection, 
medication, patient care or procedural).  Pareto diagrams were created to 
visualize the distributions of categories and types of AE. 
Patient perspective analyses:  Four distinct analyses were performed to achieve 
a full patient perspective in this study.  First was the descriptive analysis of the 
patients’ general characteristics.  Second, Cox proportional hazard analyses 
were performed between each patient-specific covariate and time to first adverse 
event. Third, the statistically significant patient-specific covariates from the 
bivariate Cox proportional hazard analyses were subjected to multivariable 
models. Finally, the timing of AEs was assessed in detail for all types.  Hazard 
functions, including competing causes, were plotted for time to first AEs.   
Study cohort characteristics: Baseline characteristics were presented as 
frequencies for categorical variables and means with standard deviations for 
continuous variables.  These were also calculated for separately for those who 
had one or more AEs and those who did not have an AE.  
Timing of adverse events and competing causes (patient’s perspective): 
To determine timing of AEs from a patient’s perspective, two histograms were 
plotted to show the count of AEs occurring on each day of the hospitalization 
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(day 1 equivalent to the first 24 hours following admission).  Histograms were 
plotted by day of first AE and day of all AEs.  Competing causes of first AEs were 
assessed through analysis of time to event distributions.  These distributions for 
time from hospital admission to first AE were assessed by fitting 2 and 3 
parameter (threshold) Weibull distributions along with lognormal and exponential 
distributions to the data. AICc, BIC, -2Loglikelihood values were used to 
determine the best fitting distribution by selecting the distribution with the lowest 
values for these parameters.   
Information gleaned from the best fitting distributions were utilized to plot 
hazard functions (h(t)).  The following were identified from the cumulative density 
function, F(t), and hazard function: fraction failing by the end of the first and 
fourth hospital day, and identification of peak periods of first-event risk. Since 
patients could have more than one type of AE during the course of their 
hospitalization, the mean cumulative function for AE recurrence was plotted 
(average number of events per patient versus time from hospital admission). 
In the assessment of competing causes, an assumption is made that all 
events and the possible causes are independent of each other. However, to 
account for correlations within subject and within hospital, the standard variance 
estimate is replaced by a robust Wald test. In the case of ties in time between 
events or time to an AE, the Breslow likelihood approximation was used.   
Patient-specific bivariate Cox proportional hazards analyses: Cox 
proportional hazards regression analyses were performed with each individual 
patient-specific covariate. The covariates tested in the bivariate comparisons are 
listed in Tables 4, 5, 6, 7 and 8.  Time to first AE (of any cause) was the primary 
outcome variable.  If no AE occurred, patients were censored at time of 
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discharge, death or transfer to the operating room for major surgery (changing 
the course of a typical HF hospitalization).  Hazard ratios were calculated with 
their 90% and 95% confidence intervals (CI).  Highly correlated covariates were 
identified and collapsed into single binary categorical variables to minimize 
potential collinearity. For example, three of the activities of daily living (ADL) with 
very similar bivariate outcomes (bathing, dressing and toileting) were collapsed 
into a single dichotomous variable “personal hygiene.”  Requiring assistance with 
any one or more of these ADL resulted in a value of requiring assistance with 
personal hygiene.   
Patient-specific multivariable Cox proportional hazards analyses: Cox 
proportional hazard regression analyses were performed to determine the 
combination of patient characteristics that most completely explained variance in 
the relationship between patient-specific covariates and the occurrence of at 
least one AE during the hospitalization. Time to first AE (of any cause) was the 
primary outcome variable.  If no AE occurred, patients were censored at time of 
discharge, death or transfer to the operating room for major surgery (changing 
the course of a typical HF hospitalization).  Hazard ratios were calculated with 
their 95% CI.  Six distinct models were built sequentially to reflect the clinician’s 
typical initial history and physical exam approach to information acquisition at the 
time of patient admission.  Only those covariates that were statistically significant 
within the 90% CI in the bivariate analyses were introduced into these 
multivariable models. Patient-specific covariates were introduced in the following 
order:  Model 1) patient pre-hospital characteristics; Model 2) past medical 
history; Model 3) admission medications; Model 4) functional status; Model 5) 
social habits; and Model 6) severity of presenting illness. For each of the six 
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models, backward elimination was used to determine the best selection of 
covariates for a particular model.  Age and gender were force fit throughout every 
model. Other covariates whose multivariate odds ratio 95% CI did not contain 
1.0, either bivariately or as a portion of an interaction term, were removed from 
further model building.  Statistically significant factors carried forward as fixed 
covariates for the subsequent model.   
Administration perspective analysis:  For the purposes of this analysis, the 
patient safety system at this hospital is the aggregate of all four SOPs – infection 
control, safe medication delivery, illness and injury prophylaxis and safe 
procedure practices.  Development of an AE was considered a failure in the 
SOPPs in place to prevent harm to hospitalized patients. From a system 
perspective it is important for hospital leadership to understand failure rates 
through time given the amount of capital, time and monetary investment put into 
safety and quality performance.   
SOPP failure modes were assumed to be independent.  Time to all AEs 
and time between all AEs (as an aggregate and by type of SOPP) were 
assessed and fit to distributions for the time period of 2005 through 2007.  
Competing causes were assessed for time between specific SOPP failure 
modes. To account for correlations within subject and within hospital, the 
standard variance estimate is replaced by a robust Wald test. Patients were 
censored from the analysis at time of discharge, death or surgery.  In the 
competing cause analysis, failures associated with one SOPP failure mode were 
also censoring times for the alternative SOPP failure modes. Information 
gathered from determination of best fit distributions was used to construct graphs 
of the hazard function (h(t)) and cumulative density function.  Peak instantaneous 
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failure rates were assessed and fraction failing at 24 hours was determined.  
From prior analyses, it was anticipated that the Weibull distribution would best fit 
the time between SOPP failures (aggregate system and individual types).  Given 
that the Weibull analysis ignores the actual order of failure times, a cumulative 
function of number of events and date of failure was also plotted. 
 Moving range statistical process control charts and analysis of variance 
tests were used to test the null hypothesis that there was no change in time 
between AEs of any SOPP failure mode through time. 
Descriptive adverse event results:  The final study cohort contained 1,722 
patients.  According to the definitions in Methods, harm occurred during 381 
hospitalizations (22.1%; 95% CI, 20.2 to 24.1) among the 1722 HF patients.  
There were a total of 566 events over 8979 patient-days (63.0 per 1000 patient-
days).  Two hundred fifty-two (14.6%) patients experienced one event, while 89 
(5.2%) experienced two events and 40 (2.3%) had 3 events or more during their 
hospitalization.  The majority of AEs (59.5%) were NCC MERP severity level E 
(transient, temporary harm with patient symptoms related to the event specifically 
documented in the medical record).  Appendix D outlines the types and 
frequencies of events identified during the two-phase medical record review.  The 
majority of AEs were medication related (43.9%).  The others were distributed 
amongst the event categories of hospital acquired infection (18.9%), patient care 
(26.3%), and procedurally related (10.9%).  Pareto diagrams demonstrating the 
types of AE within each of these categories are illustrated in Figures 4-7. 
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Figure 4: Pareto diagram: sub-types of hospital acquired infections 
 
 
Figure 5: Pareto diagram: sub-types of medication adverse events 
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Figure 6: Pareto diagram: sub-types of patient care adverse events 
 
 
Figure 7: Pareto diagram: sub-types of hospital acquired infections 
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Patient perspective analysis results 
Study cohort characteristics: Mean length of hospital stay was 5.2 + 4.8 
days with a median of 4.0 days.   The mean age of patients was 75.7 ± 12.5 
years; 96.3% were Caucasian; and 54.9% were male.  Altogether, 26.4% were 
from the local community, while 29.9% lived within a 120-mile radius immediately 
outside of the local community and 43.7% were distant referrals.  More than half 
of the patients were married (59.2%), and 84.7% lived at home.  Patients were 
taking an average of 6.2 + 3.2 prescribed medications at the time of admission.  
Their mean Charlson Index was 3.9, with an IPFS of 4.1 ± 3.7.  No patients were 
admitted with a palliative care designation and 80% were self-designated as “full 
code.”  The ejection fraction distribution was bimodal, with a mean ejection 
fraction of 42.7± 18.6%.  All of the univariate parameters assessed are 
delineated in Tables 4 - 8. 
Timing of adverse events and competing causes (patient’s perspective):  
Of those 381 patients who experienced one or more AEs during their HF 
hospitalization, 89 (23.4%) of them experienced their first AE during the first 24 
hours of their hospitalization.  Figure 8 is the histogram depicting the count of first 
AE by day of hospitalization.  In contrast, Figure 9 is the histogram illustrating the 
count of all 566 AE identified by day of hospitalization.   
Competing causes were assessed with two sets of distribution curves for 
time from admission to AE by fitting 2 and 3 (threshold) parameter Weibull 
distributions along with lognormal, threshold lognormal and exponential 
distributions to the data: time to first AE only and time to all AEs.  
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Figure 9: Count of all adverse events experienced by day of hospitalization 
(n=566) 
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The results for distribution of time from admission to first AE (Model A – patient 
perspective) for aggregate any-cause first AE with competing causes, including 
distribution paramenters, AICc, BIC, -2Loglikelihood values are displayed in 
aggregate in Figure 10, Table 9 and detailed in Appendix J. The distribution 
results, when all AEs were treated as independent events, for time from 
admission to any and all AEs (for aggregate all cause AEs and competing 
causes), including distribution paramenters, AICc, BIC, -2Loglikelihood values 
are displayed in aggregate in Figure 11, Table 10 and detailed in Appendix K.  
 
 
Figure 10: Distribution of time from admission to the absolute first SOPP 
failure per patient with competing causes 
 
The results above, evaluated only the very first AE experienced by HF patients.  
However, as mentioned in the introduction, there are four key standard operating 
procedures or processes (SOPPs) intended to keep patients safe during their 
hospitalizations. Each of these SOPPs function independently of the others and 
Color code: 
 
Red = infection 
 
Green = medication 
 
Blue = patient care 
 
Orange = procedure 
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an adverse event is considered a failure of the respective SOPP.   The following 
analysis evaluated the reliability of these SOPPs.  If a patient had more than one 
AE within a single type of SOPP, only the first event was considered a failure 
(subsequent ones were removed from the analysis).   As with the first AE, the 
evaluation of competing causes found a larger proportion of early failures in the 
medication and patient care SOPPs compared to patient care and procedural 
safe practice SOPPs.  By 1.35 days, the instantaneous failure rate of a patient 
care event drops precipitously and becomes relatively constant ranging from 
0.0000001 to 0.00000008 at 10 days for those remaining in the hospital.   
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For medication events, the instantaneous failure rate drops abruptly until 
approximately 1.9 days into the hospitalization.  At this point, it too becomes 
relatively constant at a rate of 0.000002 to 0.0000001 at 10 days for those still 
hospitalized.  Failures in infection precautions leading to hospital-acquired 




Figure 11:  Distribution of time from admission to the first SOPP failure of 
each type with competing causes 
 
In Figure 11, HF patients can be represented in more than one line or specific 
type of process failure, but only once within each specific type. Likewise, in Table 
10, patients can have more than one type of AE or SOPP failure, but only one of 
each type.  They are therefore, represented in more than one row in the data 
table for a total of 485 events in this analysis.
Color code: 
 
Red = infection 
 
Green = medication 
 
Blue = patient care 
 
Orange = procedure 
 
Black = aggregate 
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Results of patient-specific risk factor analyses:  Bivariate analysis 
identified several patient characteristics that differed between the patients who 
experienced at least one AE during the hospitalization and those who had no 
events (Appendices C-H).  The patients who resided within the local county (HR 
1.60, 95%CI 1.23-2.07) or within a 120-mile radius (HR 1.84, 95%CI 1.42-2.32) 
had a higher hazard of AEs.  Some patient characteristics that seemed to have a 
protective effect were those who lived in their own home (HR 0.52, 95%CI 0.40-
0.70), or walked independently (HR 0.24, 95%CI  0.12-0.57).  However, the 
hazard of AE was higher for those who required help with ADL’s, had a renal 
transplant (HR 2.72, 95%CI 1.23-5.11), or osteoarthritis (HR 1.48, 95%CI 1.18-
1.85).  Increased acuity of illness at time of presentation to the hospital as 
measured by the IPFS was also associated with an increased hazard of AEs (HR 
2.66, 95%CI 1.66-4.22 over entire range of regressor).  
The six successive models tested in the multivariable analysis are 
delineated in detail in Appendix I. Model 1 (pre-hospital characteristics) revealed 
increased hazard of AEs for residents of skilled nursing facilities (HR 1.75, 
95%CI 1.26-2.37), unmarried women (HR 1.15, 95%CI 1.03-1.30) and those 
residing in southeastern Minnesota (HR 1.50, 95%CI 1.19-1.48). The hazards of 
AEs for these covariates decreased slightly, but maintained statistical 
significance, in Model 2 (past medical history).  Histories of kidney transplant (HR 
3.00, 95% CI 1.34-5.79) or osteoarthritis (HR 1.32, 95% CI 1.05-1.67) were the 
only chronic medical conditions that statistically added to the model. The 
Charlson Index was not associated with increased hazard of AEs.  All tested 
covariates not reaching the 95% CI level were removed from the model.  The 
next step was to add classes of medications to the remaining covariates (Model 
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3, admission medications).  The hazard ratios and 95% CIs for home use of beta-
blockers and calcium channel blockers were less than one, representing a 
protective effect.  Whereas the hazard ratios and 95% CIs for home use of 
diuretics and allopurinol exceeded 1.0, indicating an increased hazard of AE.  
Only these four statistically significant medication classes were retained in the 
subsequent model functional status covariates were added (Model 4, functional 
status).  Dependence upon others for activities of personal hygiene (bathing, 
toileting, dressing) demonstrated an increase in hazard for AEs; however, 
dependence on either a device or another person for ambulation did not 
statistically impact the model.  However, the addition of personal hygiene 
associated ADLs (HR 1.63, 95%CI 1.25-2.11), caused pre-hospital residence in a 
nursing home to no longer be independently associated with increased hazard of 
an AEs (HR 1.15, 95%CI 0.79-1.67).  Skilled nursing facility residence was 
therefore excluded as a covariate from further analysis.  Introduction of use of 
tobacco or alcohol (Model 5, Social Habits) had no impact on the model and 
were not carried forward to subsequent models.  Finally, in Model 6 (severity of 
illness) addition of severity of illness did not statistically modify the effect size for 
existing covariates carried forward from prior models; however, a higher degree 
of organ failure and physiological instability measured by the IPFS were 
associated with increased hazard of AE (HR 1.86, 95%CI 1.14-3.02).  Systolic 
dysfunction was not associated with increased hazard of an AE in this 
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Administration perspective reliability results:  
The threshold (3 parameter) Weibull distribution was the best fit for the time 
between failures analysis through the period of the study (2005-2007).  The 
parameters and criterion of this fit are shown in Table 10.  The cumulative 
density function (CDF) is plotted in Figure 12 with its associated hazard function 
(h(t)) plotted in Figure 13. 
 
 Table 11:  Threshold Weibull distribution of time between failures of the 






The hazard function depicted in Figure 13 shows an early peak followed by a 
very steep decent of the instantaneous failure rate in the first several hours.  This 
was also the case for the competing SOP causes of failure, particularly for 
medication events.  These hazard functions can be reviewed in Appendices L-O.    
 
Parameters Criterion 




0.57 1.17 α : 1.78 
β : 0.86 
threshold:           
-4.44x10-16 
1839.57 1833.52 1852.54 
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Figure 12:  Threshold Weibull distribution of time between failures within 




Figure 13: Hazard function (h(t)) for aggregate of standard operating policy 
and procedure failures  
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Since this analysis was performed using the Weibull distribution, the actual order 
of events was not taken into consideration – making it a nonrepairable system 
analysis by default.  In order to ensure this was a proper assumption, the graph 
in Figure 14 was plotted to assess the rate of the accumulation of adverse events 
through the period of the study.  The approximate straight line indicates that the 
system is stable with a consistent rate of failure. 
 
 
Figure 14: Cumulative failures of the aggregate of standard operating 
procedures and policies during the period of study (2005-2007) 
[2005 green; 2006 blue; 2007 red] 
 
This analytic approach to assess reliability of standard practices was repeated for 
each of the four types of SOPP being evaluated for safe care delivery to 
hospitalized HF patients.  The details, including tables and figures, are delineated 
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in the appendices as follows: Appendix L – Infection control failures; Appendix M: 
Safe medication delivery failures; Appendix N: Prophylaxis against illness or 
injury failures; Appendix O: Safe procedural practice failures. 
In all cases, the instantaneous failure rate was highest very early in the 
distribution with a fairly abrupt change in slope to nearly flat.  From that point 
forward, the failure rate decreased gradually thereafter.   
 
Table 12: Hazard of recurrent failure of the standard operating procedures 
and policies for safe inpatient care of HF patients during period of study 
(2005-2007) 
  



















0.46 0.74 0.01 
Infection 107 Weibull 0.48 0.009 0.01 




Patient Care 149 Weibull 0.13 0.24 0.01 
Procedural 62 Weibull 0.07 0.08 0.1 
SOP: standard operating procedures and processes  
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The respective time points (x-axis) that marked the significant change in hazard 
function slope were as follows: infection events, 0.23 days; medication events, 
0.45 days; patient care events, 1.2 days; and procedural events, 3.1 days. 
Analysis of variance was performed to test the hypothesis that there was 
no change in time between SOP failures (aggregate or any of the competing 
causes) when comparing the three study years (2005, 2006 and 2007).  The 
results from this analysis, and those of each of the competing SOPP failure 
causes, are delineated in Table 13.  The p-values for the probability of getting a 
higher F-value than the one calculated indicate that the null hypothesis that there 
was no difference between the years cannot be rejected.  
 
Table 13: Power calculations and ANOVA results from test to determine if 
there was a change in time between SOP failures amongst the study years 
(2005, 2006 and 2007) 
 




(%) with alpha 
= 0.05 
Least significant number 
needed for 80% power 
with alpha = 0.05 
Aggregate 566 0.3779 0.6855 11.1 4490 
Infection 107 1.7719 0.1751 36.4 184 
Medication 248 1.6066 0.2027 33.8 466 
Patient 
care 
148 0.1781 0.8370 7.7 2493 
Procedural 61 0.0002 0.9998 5.0 1108604 
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However, the results of the power calculation, also listed in Table 13, reveal that 
the analysis was tremendously underpowered to detect a difference.  Therefore, 
nothing can be concluded from this analysis.   
Given the power limitations of this ANOVA analysis, a moving range 
statistical process chart was used to assess presence, or absence, of changes in 
the time between SOPP failures through time (Figure 15).  This demonstrated no 
statistical change in mean time between SOPP failures when grouped by year of 
AE occurrence. There are several points above the upper control limit suggesting 
possible special cause variation at these points. 
 
 
Figure 15: Moving range statistical process control of consecutive failures 
(aggregate of all types) in the standard operating procedures and policies 
for safe hospital care during the period of study by year (2005-2007) 
 
 




Patient-specific risk factors for adverse events: In this study of hospitalized HF 
patients, overall AEs were similar to aggregated hospital populations in ten North 
Carolina hospitals (Landrigan et al. 2010), three hospitals of a single academic 
institution in three different states (Naessens et al. 2009) and a national sample 
of Medicare beneficiaries (OIG 2010).  Although these studies all utilized the IHI 
Global Trigger Tool to identify AEs, there are some distinct differences among 
them, as shown in Table 14.   
Distributions of event types differ among the studies secondary both to 
study populations and to definitions or categorization of AEs.  Specifically, our 
study was limited to adult medical HF hospitalizations (no major surgeries 
included), leading to a lower procedure-related AE rate.  In addition, Landrigan’s 
data included events that were present on admission (Landrigan et al. 2010) 
while ours and the other studies specifically excluded events that were present 
on admission.   
To our knowledge, this is the first AE study to evaluate the interaction of 
gender and marital status in relationship to AE hazard.  Unmarried women in this 
group of HF patients demonstrated increased odds of an AE, even after 
controlling for duration of risk exposure.  We hypothesize that this increased risk 
could be due to less bedside patient advocacy given known differences in social 
support for these elderly women.  Unmarried women have been reported to have 
higher mortality rates than unmarried men for some noncardiovascular 
diagnoses; however, whenever employment is taken into account, these 
differences are distinguished (Johnson et al. 2000).  Marital status and gender 
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correlations as they relate to issues of patient safety have not been explored.  
Employment status was not included as a covariate in this study.  Further 
research (including the disciplines and expertise of the social science and 
operations management fields) is needed to understand the implications of 
increased hazard amongst unmarried women.  
Compared to other studies, we did not find the association of advanced 
age with hazard of AE (Thomas and Brennan 2000, Baker et al. 2004, Brennan 
et al. 1991).  These other studies did not include residence in a nursing home as 
a covariate.  This was a significant hazard for the patients in our study (pre-
hospital residence in a nursing home).  From our data, regardless of age, 
residing in a nursing home prior to admission carried a higher hazard than age 
alone.  Nursing home residence remained a significant hazard until daily 
functional status was added. 
This study indicates that personal hygiene-related ADLs independently 
increase the hazard of an AE, but dependence for mobility or eating does not.  A 
combination of patients’ abilities to participate in their care and the impact of ADL 
dependence on workload may explain some of this association since studies 
have shown that patients who have high participation in their care were half as 
likely to have an AE during a hospitalization (Brennan et al. 1991). Thus, the 
dependent patients in this study may have been less able to participate in their 
care, resulting in increased hazard of AE.   
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Table 14: Adverse event rate comparisons within recent GTT studies 
 Naessens et 




al.  (2010) 
OIG (2010) 






25.1 with POA 
27.0 
(95% CI) (24.4 – 29.7) (20.2 – 24.1) 
(23.1 – 27.2 
with POA) 
 
E or higher events 
per 1000 patient 
days 
 63.0 56.5 69.3 
F or higher events 
per 100 
admissions 
13.3 10.8  13.1 
(95% CI) (11.4 – 15.4) (9.4 – 12.4)  (10.9 – 15.6) 
F or higher events 
per 1000 patient 
days 
 25.5 32.9 28.0 
Event Severity*: 
  E 
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For the providers, a patient care unit is a dynamic environment of 
evolving illnesses in patients with varying degrees of ADL dependence.  Even 
among patients with similar degrees of acute illness severity, the day-to-day 
changes in patients’ personal needs create significant differences in providers’ 
work activities (Upenieks, Kotlerman and Akhavan 2007). It is unknown if the 
dynamic changes in work activities observed, while caring for patients with ADL 
dependencies, increase the number of interruptions or further divides care 
providers’ attention, both factors known to increase the likelihood of errors for 
pharmacists and nurses (Holden et al. 2010, Flynn et al. 1999, Grasha and 
Schell 2001, Holden et al. 2011). Hurst reported that lower quality of care was 
associated with fluctuating workloads (Hurst 2005).  Nurses bear the brunt of the 
daily needs required by our hospitalized patients; however, further research is 
required to understand the impact of patients’ dependencies on a hospital’s 
ability to deliver safe care. 
 Of all the past medical history comorbidities evaluated in the analyses, it 
is interesting that only presence of osteoarthritis and kidney transplant remained 
independently related to hazard of AE.  The osteoarthritis is consistent with the 
need for assistance with personal hygiene ADL’s because arthritis limits mobility 
and function by definition.  However, history of kidney transplant is a unique 
finding. There were only 18 patients in this study who had received a kidney 
transplant.  Eight of them (44.4%) experienced an AE.  This remained an 
increased hazard for these patients even after introducing all medications, other 
comorbidities, social factors, code status and severity of illness into the model.  
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 The most common adverse medication events experienced by this cohort 
of hospitalized HF patients were bradycardia and hypotension.  These are the 
most prevalent side effects of medications commonly used in treatment of 
patients with HF.  However, there was a protective effect (decreased hazard of 
AE) for those patients who were taking calcium channel and beta-blockers prior 
to admission to the hospital.  This suggests that patients who were not used to 
the effects of these medications were vulnerable to treatment doses of these 
medications typically given for acute episodes of HF.  This distinguishing feature 
of no prior use could be helpful to providers when determining the most 
appropriate dose to prescribe in the acute hospital setting.  It suggests that a 
titration approach (starting with smaller doses and gradually increasing as 
physiologic tolerance allows) would be safer for acutely hospitalized HF patients.  
Of typical HF medication regimens, only prior use of diuretics carried an 
increased hazard of AE.  One unexpected home medication that was related to 
an increased hazard of AE was allopurinol, even after accounting for 
comorbidities and functional status.  This medication is used to decrease 
frequency of gout recurrence.   
Patient’s perspective of adverse event hazard:  To our knowledge, this is the first 
study to demonstrate instantaneous failure rates (h(t)) and the cumulative 
distribution function (F(t)) of AEs from a hospitalized HF patient’s perspective.  In 
the competing cause analysis, the distributions of time from admission to the first 
SOPP failure of any cause and the first SOPP failure of each type were plotted 
and assessed.  In both cases patients were more likely to experience medication, 
then patient care-related AE during the first 4 days of hospitalization (median 
length of hospital stay was 4.0 days).  In assessing the competing cause 
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distributions of mean time from admission to the absolute first SOPP failure, the 
three-parameter Weibull distribution was the best fitting distribution for infections, 
medication events and patient care events.  However, if the first SOPP failure 
was a procedural event, then the threshold lognormal distribution was the best fit.  
Both medication and patient care AEs revealed very early failure periods with 
rapid descents to a constant random failure rate.  For medications SOPP failures, 
the transition to a constant rate occurs prior to the end of the first day of 
hospitalization.  This indicates that the highest hazard for a medication event to 
be the cause of the first SOPP failure occurs during presentation to the hospital 
when providers are the most aggressive regarding the treatment of acute 
symptoms.  On the other hand, the hazard of infections as the cause of the first 
AE (three-parameter Weibull distribution β=1.3) increases with time and the 
failure rate of procedural events being the cause of the first AE (three-parameter 
Weibull distribution β=1.99) increases linearly with time.  The latter, with a β 
parameter approximately equal to 2 could be referred to as a Rayleigh 
distribution. (Elsayed 1996)  This distribution is most commonly seen with 
traditional mechanical components in non-healthcare related industry (Yang 
2007).   
 The instantaneous failure rates for two relevant periods of time in the 
hospital for patients (end of first day and day of median length of stay) were 
summarized in Tables 9 and 10.  There was only one other study in the medical 
literature that discussed harm as a function of hospital day (Hauck 2011). The 
investigative team used an econometric approach and identified a risk of 5.5% 
for a medication event, 3.5% for decubitus ulcers and 17.6% for hospital acquired 
infections over the course of the hospitalization.  These numbers are significantly 
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different from this study likely secondary to both analytic methodology and 
definitions of AE.  They utilized ICD10 administrative codes to identify their AE 
and did not perform any degree of clinical record review.  Their methodology also 
did not allow them to perform a time-dependent analysis as they did not have 
dates and times of the AE.  So their report of an additional risk of 0.5% per 
additional night in the hospital for a medication AE does not take into account the 
time to event statistical distributions reported in our research.  For example, our 
analysis shows that the instantaneous hazard of medication AE drops 
precipitously in the first 24 hours and becomes constant and very low at this 
point.  The rate is not the same the first night compared to all of the others. 
Limitations: Referral bias is a concern when interpreting clinical study results 
from academic medical centers.  Studies have demonstrated that clinical 
outcomes can differ depending on patients’ distance from the health care 
institution and therefore need for primary or tertiary level care (Seferian et al. 
2008, Kokmen et al. 1996, Ballard et al. 1994).  Covariates were introduced to 
assess for geographical distance from our institution’s hospital out of concern 
that AE rates may be inflated by referral or selection bias.  The results were 
counter to this traditional view of referral bias.  Indeed, the hazard of an AE 
occurrence was higher for those who resided within the 120-mile radius of the 
hospital, compared to those who lived beyond that distance.  This is counter 
intuitive and was present even with severity of illness, comorbidities and 
functional status in the Cox model.  The numerical values of the hazard ratios 
were compared before and after the addition of the geographic covariate. The 
presence of this possible reverse-referral bias did not meaningfully alter the 
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performance of any other patient-specific covariate in the Cox regression model, 
as the hazard ratios remained largely unchanged. 
This study has many weaknesses and limitations.  AEs related to a 
hospitalization may only become evident after the patient is dismissed from this 
hospital.  AE can be accurately identified with post-hospitalization surveys 
(Weissman and Schneider 2008); but we did not employ this methodology and 
may therefore have underestimated the number of events occurring during the 
hospitalization.  The only post-discharge discoveries of AEs possibly detectable 
in this study were those necessitating an emergency department visit or 
rehospitalization.  These unplanned readmissions and visits to the emergency 
department within 30 days of discharge from the index hospitalization are triggers 
in the GTT.   
Another limitation of this study is the questionable reliability of AE 
identification through the use of a retrospective medical record review.  The use 
of the GTT methodology requires interpretation by providers not involved in the 
care.  It also requires judgments to be made about care not fully documented in 
the medical record.  We attempted to adjust for this inherent measurement bias 
by using objective definitions for dependent variables, minimizing interpretation 
required for identification of an event.  The nurses and physician reviewers were 
consistent throughout the study. The triggers were used to stimulate a focal in-
depth review for documented events and we utilized multiple blinded reviewers 
with a software tool that guided reconciliation of differences of reviewers’ 
opinions. Both a local study (Naessens et al. 2010) and Landrigan et al. (2010) 
found the GTT to have adequate inter-rater reliability.  
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There are two other challenges leading to possible under-identification of 
AEs.  Naessens et al. (2009) published evidence that the GTT does not identify 
all AE.  There were events voluntarily reported by staff and others identified with 
the AHRQ’s PSI algorithm that were not discovered by the GTT.  One possible 
cause is that the GTT triggers identify AEs that occur as a result of acts of 
commission (e.g. hypotension developing after a medication is delivered or 
infection from a urinary catheter inserted).  Events related to acts of omission 
(e.g. inadequate antimicrobial coverage for a health care acquired infection or 
delayed recognition of acute physiological deterioration and delayed intervention) 
may not be readily identified through the GTT methodology.  One other factor 
that may have caused us to underestimate the number of events was the strict 
adherence to the study definition of AEs.  In order for an event to be considered 
an AE, there had to be written documentation of patient symptoms.   For 
example, if there were two patients with the same level of hypoglycemia following 
insulin dosing, but only one had documented symptoms, then only this one would 
be considered an AE. 
The use of the GTT poses another significant definition of AE challenge 
for study interpretation.  The study defined presence or absence of AE by patient 
symptoms; hence, the time of the AE in this study is the time of the clinical 
manifestation of the SOPP failure, not the actual inciting event itself.  This has 
little bearing on the time-fixed, patient-specific characteristics used in this 
research.  However, future investigations evaluating the timing of clinical care 
interventions with the AE will require adjustment of the time of event so as to not 
confuse statistical relationships.  As an example, suppose an infectious AE, 
identified by patient symptoms, is timed to have occurred in the data set 2 hours 
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after transfer to an ICU. Assignment of the responsibility of this infectious AE to 
the ICU would be clinically suspect.  It takes hours, or maybe even days, for 
symptoms to develop after infectious agent is introduced.  Therefore, for this 
scenario, it is likely that the infection was acquired prior to transfer to the ICU.  
The interpretation for the clinical practice is significantly different: the patient was 
transferred to the ICU because of a hospital-acquired infection versus the patient 
obtained a hospital-acquired infection in the ICU. 
Another serious limitation of this study is lack of generalizability of results 
given the primarily Caucasian population.  African Americans have been shown 
to have both a higher incidence of HF (Bahrami et al. 2008, Lloyd-Jones et al. 
2010) and AEs. (Brennan 1991a, Brennan 1991b, Chang et al. 2005)  It is 
unclear if racial disparity is an issue in these HF patients, as this study did not 
have the power to detect differences in this covariate. 
Summary: Hospitalized HF patients in this study cohort were more likely to 
experience failures in the SOPP for safe medication delivery and illness or injury 
prevention (patient care events) in the first week of hospitalization (median length 
of stay is 4.0 days). The hazard functions (h(t)) for AEs in both of these SOPP 
followed three-parameter Weibull distributions and had early failure periods with 
precipitous drops in instantaneous failure rate within the first 24 hours of 
hospitalization.  AEs resulting from failures in the infection control and universal 
precautions for safe procedural SOPP occur relatively later with a failure rate that 
increases with time. 
 From the hospital administration’s perspective, time between aggregate 
all-SOPP failures, or of the individual SOPP types, did not change through the 
three-year period of this study.  The study was not powered to assess 
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performance differences between years using analysis of variance.  Utilizing a 
moving range statistical process control chart, there were some possible points 
of special cause variation with an elevated number of days between failures.  
Investigation into these time periods may yield some insight into possible 
circumstances or factors that increase reliability of SOPP performance.  
However, retrospective evaluation of the hospital environment between 2005-
2007 would likely prove difficult and effort may be better expended with more 
real-time monitoring. 
Within the HF study cohort, several patient-specific characteristics were 
found to be associated with increased hazard of an inpatient AEs:  history of 
osteoarthritis or kidney transplant, use of allopurinol, the need for assistance with 
personal hygiene-related ADL’s, and higher severity of acute illness measured by 
the IPFS.  These particular comorbidity and functional status findings are new 
findings for the medical literature. Marital status modulated the risk of AEs for 
women; with a significant increase in hazard for unmarried women.  This, too, is 
a new finding.  In an exploratory analysis, we created a logistic regression model 
for risks of one or more AEs using the statistically independent covariates from 
this analysis.  Prior to controlling for length of hospital stay, less than 8% of the 
model variance is explained with patient-specific factors.  After length of stay was 
introduced into the model, the R-squared was still only approximately 22% with 
an area under the curve (AUC) of 0.809.  Important determinants of risk remain 
to be identified.  There is a significant amount of research that must occur to 
identify our health care system’s vulnerabilities and define interventions to 
meaningfully mitigate future AEs. 
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Conclusion: Health care standard operating policies and procedures for 
prevention on inpatient harm do not function at the high levels of reliability 
expected in other industries. Operations research is needed to elucidate 
constellations of health care delivery system factors increasing the risks of AEs.  
Only then, will we be able to define specific interventions to mitigate harm and 
meaningfully improve the reliability of hospital care delivery in the United States.  
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Principal Investigator Notification: 
From: IRB 
To: Jeanne Huddleston  
CC: Study Team Members that are marked as wishing to receive 
correspondence regarding the protocol/grant application 
  
Re: Application # 07-003607 
 07-003607  
Please note that all correspondence (modifications, progress reports, reportable 
events) related to this study/grant application must be submitted electronically in 
the IRBe system.  
 
The following is an excerpt from the minutes of the Expedited Review A of the 
Mayo Clinic Institutional Review Boards meeting dated 5/22/2007: 
The Committee reviewed and approved for human studies the protocol entitled 
"Health Care Delivery and Harm to Hospitalized Congestive Heart Failure 
Patients" from Dr. Jeanne Huddleston. The Committee noted that the human 
studies aspects involve a retrospective chart review of Mayo Clinic Rochester 
patients having been hospitalized from January 1, 2005 to May 22, 2007 with a 
primary diagnosis of congestive heart failure (CHF). The Committee reminds the 
proponents to submit a modification to include participants hospitalized from May 
23, 2007 to December 31, 2007, as the request in this application is to 
retrospective collect data and therefore the Committee cannot approve 
prospective collection of data. The Committee noted Dr. John Fowler from 
Arizona State University will serve as an external collaborator receiving de-
identified data. Dr. Huddleston is reminded that no Mayo patient identifying 
information may be released to the external collaborator. It should also be noted 
that this approval is valid only for Mayo investigator activities. The IRB approves 
waiver of specific informed consent in accordance with 45 CFR 46.116 (d) as 
justified by the investigator, and waiver of HIPAA authorization in accordance 
with applicable HIPAA regulations. The Committee determined that this 
constitutes a minimal risk collection of data or specimens that have already been 
collected for non-research purposes, and therefore was eligible for expedited 
review in accordance with 45 C. F. R. 46.110 (b) (1) and 63 FR 60364, item 5. 
This approval is valid for exactly one year unless during the year the IRB 
determines that it is appropriate to halt or suspend the study earlier. 07-003607 
 
 
Rubin, Joseph M.D. , Chair 
Gina Dahlgren , Specialist 
Mayo Clinic Institutional Review Boards 
Expedited Review A 








Note: Categories of probable and definite were included as adverse medication events in 
this study. 
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Cares Module Triggers + Event Category 






Transfusion or use of 
blood products 
  C. difficile positive   
Any Code or arrest   PTT >100 seconds   
Dialysis   INR >6    
Positive blood culture    Glucose < 50 mg/dl   
X-Ray or Doppler 
studies  for emboli  
  Rising BUN/S.Creat 
>2X base 
  
Abrupt drop in Hct>4% 
or Hg >gms 
  Benadryl 
(Diphenhydramine)use 
  
Patient fall   Vitamin K 
administration 
  
Decubiti   Romazicon 
(Flumazenil) use 
  
Readmission within 30 
days 
  Narcan (Naloxone ) use   
Restraint use   Antiemetic use   
Infection of any kind   Over 
sedation/hypotension 
  
In hospital Stroke   Abrupt medication stop   
Transfer to higher level 
of care 
  Other   
Any procedure 
complication 
     
Other   ICU Module Triggers   
   Pneumonia onset   
Surgical Module 
Triggers* 
  Readmission to ICU   
Return to surgery    In unit procedure   
Change in procedure   Intubation/reintubation   
Admission to ICU post 
op 
     
Intubation/Reintub/BiPap 
in PACU 
  OB Module*   
X-ray intra-op or in  
PACU 
  Apgar < 7 at five 
minutes 
  
Intra or post-op death     Maternal/neonatal 
transport/transfer 
  
Mech Vent >24 hours 
post op 
 *Not utilized for 
this study 
Mg Sulfate or 
terbutaline use 
  
Intra-op epi or nor epi 
use 
  Infant serum glucose 
<50 
  
Post-op Troponein level 
> 5 





  Induction of delivery   
Consult requested in 
PACU 
     
Path report normal or 
unrelated to dx 
  ER Module   
Insertion of art or CVP 
during surgery 
  Readmission to ED 
within 48 hours 
  
Operative time > 6 hours   Time in ED > 6 hours   
Removal/Injury or repair      
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Adverse Event Category % of all adverse events 
Infection 18.9% 
 types of infections   





 Catheter associated UTI  62.3%  





 Clostridium Difficile  2.8%  










 Procedure site infection  0.9%  
 Other  0.9%  
Medication 43.9% 
 types of medication events   
 Acute kidney injury  22.1%  
 Arrhythmia  1.6%  
 Allergy  8.0%  
  Sub-types of allergies   
  Rash (95%)    
  Anaphylaxis (5%)    








 Coagulopathy  15.7%  
  Sub-types of coagulopathy   
  Epistaxis (7.7%)    
  GI bleed (33.3%)    
  Hematoma (18%) 
(nonprocedural)  
  
  Hematuria (18%)    
  Hemoptysis (10.3%)    
  Intracranial hemorrhage (12.8%)    
 Digoxin toxicity  1.2%  
 Hypoglycemia  8.0%  
 Hypotension  20.1%  
 Medication Error  2.0%  
  Sub-types of medication errors   
  Wrong dose (60%)    
  Wrong patient (20%)    
  Wrong medication (20%)    
 Mental status changes  8.4%  
  
Sub-types of mental status 
changes  
 
  Delirium/hallucinations (68.2%)    
  Lethargy or somnolence (31.8%)    
 Respiratory failure  4.8%  
 Electrolyte abnormalities  0.4%  
 Other  4.4%  
 




Patient Care 26.3% 
 types of patient care events   
 Fall  8.3%  
 Decubiti  1.4%  
 Device failure or malfunction  36.6%  
 Pulmonary embolus  1.4%  
 Plan of care  0.7%  
 Readmission  33.1%  
  Sub-types of readmission 
events 
  
Premature discharge (25.5%)  
  Medication change (48.4%)   
  Monitoring (0.1%)   
  Other (0.5%)   
 Respiratory failure  5.5%  
 Triage  4.8%  
 Other  8.3%  
Procedure 10.9% 
 types of procedure events (%)  
 Bleeding at puncture site  11.3  
 Hematoma  38.7  
 Pseudoaneurysm  4.8  
 Wrong site  1.6  
 Pneumothorax  4.8  
 Other  38.7  





SUMMARY OF PATIENT PRE-HOSPITAL CHARACTERISTICS 
INCLUDING RESULTS OF UNIVARIATE AND BIVARIATE ANALYSES




Of those with and without 
adverse events, comparison 
of patient factors between 
these two subgroups 



















Age - mean(sd)  75.8 (12.4) 75.7 (12.6) 75.8 (12.1) Per unit change: 
1.01 (1.00-1.02) 
Per change over 
entire range: 
2.28 (1.19-4.41) 
Race – Caucasian  1649 (96.3%) 1286 (96.3%) 369 (96.9%) 1.25 (0.74-2.35) 
BMI – mean(sd) 1 30.2 (8.0) 30.2 (7.7) 31.6 (9.1) Per unit change: 
1.01 (1.00-1.02) 




     Olmsted 
County 
     SEMN 

















Married  1019 (59.2%) 810 (60.4%) 209 (54.9%) 0.78 (0.63-0.95) 
Male  945 (54.9%) 749 (55.9%) 196 (51.4%) 1.00 (0.82-1.22) 
Code status - Full 8 1371 (80.0%) 1072 (80.3%) 299 (78.9%) 0.77 (0.61-1.00) 




Walk with device 
Wheelchair 
independently 












































































































Current Tobacco   162 (9.4%) 127 (9.5%) 35 (9.2%) 0.97 (0.68-1.36) 
Current ETOH use  452 (26.3%) 367 (22.4%) 85 (22.5%) 0.81 (0.63-1.03) 
*, Reference variable; sd: standard deviation; AE: adverse event; AL: assisted living; SNF: skilled 
nursing facility; ADL: activity of daily living; IPFS: Inpatient Physiology Failure Score; EF: ejection 
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  Of those with and without 
adverse events, comparison of 
patient factors between these 








event          
(n=1341) 
With adverse 





875 (65.6%) 273 (72.4%) 1.17 (0.93-1.47) 
Potassium 
supplementation 
220 (12.8%) 165 (12.4%) 55 (14.6%) 0.91 (0.68-1.20) 
ACE-I or ARB 928 (54.2%) 739 (55.4%) 189 (50.1%) 0.96 (0.81-1.21) 
Hydralazine 42 (2.5%) 29 (2.2%) 13 (3.4%) 1.30 (0.71-2.17) 
Beta blocker 1096 
(64.1%) 
868 (65.1%) 228 (60.5%) 0.86 (0.70-1.05) 
Calcium channel 
blocker 
354 (20.7%) 285 (21.2%) 69 (18.3%) 0.87 (0.67-1.13) 
Digoxin 403 (23.6%) 299 (22.4%) 104 (27.6%) 0.86 (0.68-1.08) 
Nitrates 284 (16.6%) 227 (17.0%) 57 (15.1%) 1.01 (0.76-1.33) 
Amiodarone 111 (6.5%) 81 (6.1%) 30 (8.0%) 1.03 (0.70-1.46) 
Allopurinol 192 (11.2%) 134 (10.0%) 58 (15.4%) 1.37 (1.03-1.80) 
Coumadin 620 (36.2%) 473 (35.5%) 147 (39.0%) 1.86 (0.68-1.30) 
Aspirin 913 (53.4%) 721 (54.0%) 192 (50.9%) 1.04 (0.85-1.27) 
Other antiplatelet 191 (11.2%) 150 (11.2%) 41 (10.9%) 1.12 (0.80-1.53) 
NSAID 51 (3.0%) 39 (2.9%) 12 (3.2%) 1.47 (0.78-2.49) 
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Insulin 318 (18.6%) 230 (17.2%) 88 (23.3%) 1.25 (0.98-1.58) 
Oral diabetes 
medication 
214 (12.5%) 170 (12.7%) 44 (11.7%) 0.87 (0.63-1.18) 
GI protection 614 (35.9%) 473 (34.5%) 141 (37.4%) 1.07 (0.87-1.32) 
Antidepressant 402 (23.5%) 310 (23.2%) 92 (24.4%) 1.11 (0.87-1.39) 
ACE-I: Angiotensin converting enzyme inhibitor 
ARB: Angiotensin II receptor blocker 
NSAID: Nonsteroidal anti-inflammatory drug  
Other antiplatelet: ticlopidine, clopidigrel, prasugrel, dipyridamole 
Oral diabetes medications: sulfonylureas, biguanides, thiazolidinediones, alpha-
glucosidase inhibitors, meglitinides, dipeptidyl peptidase IV inhibitors 
GI protection: Histamine 2 receptor blocker or proton pump inhibitor 
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APPENDIX H 
SUMMARY OF PATIENT SEVERITY OF ILLNESS AT ADMISSION 
INCLUDING RESULTS OF UNIVARIATE AND BIVARIATE ANALYSES 
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   Of those with and without 
AEs, comparison of patient 
factors between these two 





 Missing Overall 
(n=1722) 
No AE          
(n=1341) 







 3.9 (2.7) 
 
3.9 (2.6) 4.2 (2.8) Per unit change:  
1.02 (0.98-1.06) 
Per change over 
entire range: 
1.38 (0.76-2.45) 
IPFS – mean 
(sd) 
 4.1 (3.7) 3.8 (3.5) 5.2 (4.0) Per unit change:  
1.05 (1.03-1.08) 









42.6% (18.6) 42.7% 
(18.6) 
Per unit change:  
1.00 (1.00-1.01) 





EF < 40% 
14 761 
(44.8%) 
599 (45.1%) 168 (44.1%) 0.85 (0.70-1.05) 
sd: standard deviation; IPFS: Inpatient Physiology Failure Score; EF: ejection fraction 
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APPENDIX I 
MULTIVARIATE COX PROPORTIONAL HAZARD MODEL 
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APPENDIX J 
COMPETING CAUSES AND DISTRIBUTION COMPARISONS FOR TIME TO 
THE FIRST ADVERSE EVENT PER PATIENT  
(EACH PATIENT COUNTED ONLY ONCE) 





Figure J1: Competing cause distributions of time between admission and 
the first adverse event of each individual type and their aggregated 
distribution 
Red: TH Weibull distribution of Infection causes 
Green: TH Weibull distribution of medication causes 
Blue: TH Weibull distribution of patient care causes 
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Figure J2: Threshold Weibull cumulative frequency distribution for those 
first adverse events (F(t) estimate) that are infections  
 
 
Figure J3: Hazard function (h(t)) for those first adverse events that are 
related to infectious control failures  
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Figure J4: Threshold Weibull cumulative frequency distribution for the 
portion of first adverse events (F(t) estimate) that are medication events 
 
 
Figure J5: Hazard function (h(t)) for those first adverse events that are 
related to safe medication process failures 
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Figure J6: Threshold Weibull cumulative frequency distribution for the 




Figure J7: Hazard function (h(t)) for those first adverse events that are 
related to safe patient care process failures  

























Figure J8: Threshold Weibull cumulative frequency distribution for the 
portion of  first adverse events that are procedural events (F(t) estimate) 
 
 
Figure J9: Hazard function (h(t)) for patient care injury prophylaxis failures  








COMPETING CAUSES AND DISTRIBUTION COMPARISONS FOR TIME TO 
THE FIRST ADVERSE EVENT OF EACH TYPE  
(PATIENTS MAY HAVE MORE THAN ONE ADVERSE EVENT,  
BUT ONLY THE FIRST OF EACH TYPE IS INCLUDED 
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This analysis includes the first of every type of adverse event for each patient.  
There are a total of 485 AE representing SOPP failures included in these 
distributions (99 infections, 200 medication events, 131 patient care events and 
55 procedural events).  If a patient had more of one type of event (e.g. two 
medication events), only the first of that type was included.   
 
Figure K1: Competing cause distributions of time between admission and 
the adverse events of each individual type with their aggregated 
distribution (patients can be counted once in each type of AE) 
Red: Exponential distribution of Infection causes; Green: TH Weibull distribution 
of medication causes; Blue: TH Weibull distribution of patient care causes; 
Orange: TH lognormal distribution of procedure causes 
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Figure K2: Exponential cumulative frequency distribution for first infection 
adverse events (F(t) estimate) experienced by HF patients 
 
 
Figure K3: Hazard function (h(t)) for infection control SOPP failures  
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Figure K4: Threshold lognormal cumulative frequency distribution for first 
procedural adverse events (F(t) estimate) experienced by HF patients 
 
 
Figure K5: Hazard function (h(t)) for safe procedural SOPP failure 
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Figure K6: Threshold Weibull cumulative frequency distribution for first 
medication SOPP failure experienced by HF patients (F(t) estimate) 
 
 
Figure K7: Hazard function (h(t)) for safe medication delivery SOPP failures 
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Figure K8: Threshold Weibull cumulative frequency distribution for first 
patient care injury prophyalxis SOPP failure experienced by HF patients 
(F(t) estimate) 
 
Figure K9: Hazard function (h(t)) for patient care injury and illness 
prophylaxis SOPP failures 

























ADMINISTRATION PERSPECTIVE: ANALYSIS OF FAILURES IN STANDARD 
POLICIES AND PROCEDURES FOR INFECTION CONTROL FOR 
HOSPITALIZED PATIENTS THROUGH DURATION OF STUDY (2005-2007) 
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Table L1: Parameters and fit criterion for Weibull distribution of time (days) 






Figure L1: Weibull distribution of time (days) between recurrent hospital 
acquired infections through period of study (2005 – 2007) 
Parameters Criterion 




0.47 1.09 α : 1.59 
β : 0.92 
325.95 321.83 331.18 
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Figure L2: Hazard of recurrent failure of the standard operating procedures 




Figure L3: Cumulative failures of the standard operating procedures and 
policies for infection control during the period of study (2005-2007) 




Figure L4: Moving range statistical process control of consecutive failures 
in the standard operating procedures and policies for infection control 













Figure L5: ANOVA of time between failures of the standard operating 
procedures and policies for infection control during the period of study by 
year (2005-2007) 
Prob > F  
0.17  
   
120 
APPENDIX M 
ANALYSIS OF FAILURES IN STANDARD POLICIES AND PROCEDURES FOR 
SAFE MEDICATION DELIVERY FOR HOSPITALIZED PATIENTS THROUGH 
TIME PERIOD OF STUDY (2005-2007) 
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Table M1: Parameters and fit criterion for threshold Weibull distribution of 





Figure M1: Threshold Weibull distribution of time (days) between recurrent 
medication events through period of study (2005-2007) 
Parameters Criterion 




0.60 1.18 α : 1.83 
β : 0.84 
threshold:         
-4.44x10-16 
825.43 819.33 835.87 
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Figure M2: Hazard of recurrent failure of the standard operating procedures 
and policies for safe medication practices during the period of study (2005-
2007) 
 
Figure M3: Cumulative failures of the standard operating procedures and 
policies for safe medication practices during the period of study (2005-
2007) 
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Figure M4: Moving range statistical process control of consecutive failures 
in the standard operating procedures and policies for safe medication 











Figure M5: ANOVA of time between failures of the standard operating 
procedures and policies for safe safe medication practices during the 
period of study by year (2005-2007) 
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APPENDIX N 
ANALYSIS OF FAILURES IN STANDARD POLICIES AND PROCEDURES FOR 
SAFE MEDICATION DELIVERY FOR HOSPITALIZED PATIENTS THROUGH 
TIME PERIOD OF STUDY (2005-2007) 




Figure N1: Weibull distribution of time (days) between recurrent patient 
care events through period of study (2005-2007) 
 
 
Figure N2: Hazard of recurrent failure of the standard operating procedures 
and policies for prophylaxis against patient care events during the period 
of study (2005-2007) 
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Figure N3: Cumulative failures of the standard operating procedures and 




Figure N4: Moving range statistical process control of consecutive failures 
in the standard operating procedures and policies for prophylaxis against 
patient care events during the period of study (2005-2007) 
   
127 
 
Figure N5: ANOVA of time between failures of the standard operating 
procedures and policies for prophylaxis against patient care events during 
the period of study by year (2005-2007) 
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APPENDIX O 
ANALYSIS OF FAILURES IN STANDARD POLICIES AND PROCEDURES FOR 
SAFE PROCEDURES FOR HOSPITALIZED PATIENTS THROUGH TIME 
PERIOD OF STUDY (2005-2007) 
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Table O1: Parameters and fit criterion for Weibull distribution of time (days) 





Figure O1: Hazard of distribution of time (days) between recurrent 
procedural events through period of study (2005 – 2007) 
 
Parameters Criterion 




2.82 1.08 α : 16.81 
β : 0.93 
474.26 470.05 478.27 
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Figure O2: Hazard of recurrent failure of the standard operating procedures 
and policies for safe procedures during the period  
 
Figure O3: Cumulative failures of the standard operating procedures and 
policies for safe procedures during the period of study (2005-2007) 




Figure O4: Moving range statistical process control of consecutive failures 
in the standard operating procedures and policies for safe procedures 
during the period of study by year (2005-2007) 
 
 
Figure O5: ANOVA of time between failures of the standard operating 
procedures and policies for safe procedures during the period of study by 
year (2005-2007) 
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